Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

A genetic variation that may indicate a patient's risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is one of several medical discoveries scientists at cancer diagnostics leader Quest Diagnostics will present during the 51st American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2009, in New Orleans, LA.

4 Dec 2009

Allos Therapeutics to launch the COMPLETE registry for patients with PTCL

Allos Therapeutics, Inc. today announced the launch of an international registry designed to address the urgent need to better understand treatment patterns and outcomes for patients with peripheral T-cell lymphoma (PTCL). The registry, known as COMPLETE (Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment), is a global observational study that will enroll patients with newly-diagnosed PTCL and obtain data regarding longitudinal treatment patterns and outcomes.

3 Dec 2009

Lunasin may have important health benefits, two new studies report

Two new University of Illinois studies report that lunasin, a soy peptide often discarded in the waste streams of soy-processing plants, may have important health benefits that include fighting leukemia and blocking the inflammation that accompanies such chronic health conditions as diabetes, heart disease, and stroke.

3 Dec 2009

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

Bristol-Myers Squibb Company today announced that more than 80 abstracts highlighting compounds from the company’s oncology portfolio will be presented at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held December 5-8 in New Orleans.

3 Dec 2009

New study links cigarette smoking with colorectal cancer

New study results strengthen the evidence that people who smoke cigarettes over a long period of time have an increased risk for developing colorectal cancer, even after adjusting for other risk factors.

3 Dec 2009

Researchers discover ability of stem cells in brain cancer glioma to resist radiation therapy

Duke University Medical Center researchers have figured out how stem cells in the malignant brain cancer glioma may be better able to resist radiation therapy. And using a drug to block a particular signaling pathway in these cancer stem cells, they were able to kill many more glioma cells with radiation in a laboratory experiment.

2 Dec 2009

FDA approves revised clinical trial protocol for CytRx' arimoclomol

CytRx Corporation, a biopharmaceutical company, is permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), following the U.S. Food and Drug Administration’s (FDA) acceptance of a revised clinical trial protocol.

2 Dec 2009

S*BIO to present data on its novel oral JAK2 inhibitor at The American Society of Hematology meeting

S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans.

2 Dec 2009

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009

University of Texas M.D. Anderson Cancer Center and Stemline Therapeutics enter into research collaboration

Stemline Therapeutics, Inc., a private clinical stage biopharmaceutical company and leading developer of oncology compounds directed to cancer stem cells, today announced that The University of Texas M.D. Anderson Cancer Center (Houston, TX) and Stemline have entered into a research collaboration.

2 Dec 2009

ASH Annual Meeting to showcase latest research and treatments for blood disorders

The American Society of Hematology (ASH), the world's largest professional association of blood specialists, expects more than 20,000 attendees at the 51st ASH Annual Meeting from December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA. The meeting will showcase the latest research and treatments for blood disorders.

2 Dec 2009

New approach to identify molecules that prevent immune cells from attacking body

A study led by a Scripps Research Institute scientist describes a new, highly pragmatic approach to the identification of molecules that prevent a specific type of immune cells from attacking their host. The findings add a powerful new tool to the ongoing search for potential treatments for autoimmune diseases, such as multiple sclerosis (MS), as well as blood cancers, such as myeloid leukemia.

2 Dec 2009

DiaMedica to acquire all issued and outstanding shares of Sanomune

DiaMedica Inc. (TSX VENTURE:DMA)("Diamedica"), a biopharmaceutical company that has discovered and is developing a novel approach to treating diabetes, announces it has entered into a non-binding letter of intent to acquire all of the issued and outstanding shares of Sanomune Inc.

2 Dec 2009

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

Cell Therapeutics, Inc. (CTI) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present new data on the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) at the 51st Annual Meeting of the American Society of Hematology on Saturday, December 5, 2009 in New Orleans, Louisiana.

2 Dec 2009

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

Memgen announced today that results from its ongoing, Leukemia & Lymphoma Society co-sponsored clinical trial in chronic lymphocytic leukemia (CLL) have been selected for an oral presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

2 Dec 2009

Study of Acetadote Injection as a cost-saving treatment for acetaminophen poisoning published

Cumberland Pharmaceuticals Inc. announced today that an independently conducted study of Acetadote (acetylcysteine) Injection, or intravenous N-acetylcysteine, as a cost-saving treatment for acetaminophen poisoning was published in Volume 12, Number 4 of the peer-reviewed Journal of Medical Economics, distributed in December.

2 Dec 2009

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.

1 Dec 2009

FORMA Therapeutics closes Series B financing to a total of $25.5 million

FORMA Therapeutics today announced that it has closed on a Series B financing that raised a total of $25.5 million. The round was led by new investor Lilly Ventures, with participation from existing investors Novartis Option Fund and Bio*One Capital of Singapore.

1 Dec 2009

Despite reservations, smoking ban has not increased children's exposure to secondhand smoke

A new study has shown that the introduction of smoke-free legislation has not led to an increase in children's exposure to secondhand smoke in their own homes.

1 Dec 2009

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

ChemGenex Pharmaceuticals Limited announced today that updated clinical data from several of its clinical trials with Omapro™ (omacetaxine mepesuccinate) will be presented at the upcoming 51st American Society of Hematology Annual Meeting in New Orleans, Louisiana.

1 Dec 2009

Leukemia News and Research

Further Reading

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

Allos Therapeutics to launch the COMPLETE registry for patients with PTCL

Lunasin may have important health benefits, two new studies report

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

New study links cigarette smoking with colorectal cancer

Researchers discover ability of stem cells in brain cancer glioma to resist radiation therapy

FDA approves revised clinical trial protocol for CytRx' arimoclomol

S*BIO to present data on its novel oral JAK2 inhibitor at The American Society of Hematology meeting

New data demonstrating the strength of Novartis' hematology portfolio to be presented

University of Texas M.D. Anderson Cancer Center and Stemline Therapeutics enter into research collaboration

ASH Annual Meeting to showcase latest research and treatments for blood disorders

New approach to identify molecules that prevent immune cells from attacking body

DiaMedica to acquire all issued and outstanding shares of Sanomune

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

Study of Acetadote Injection as a cost-saving treatment for acetaminophen poisoning published

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

FORMA Therapeutics closes Series B financing to a total of $25.5 million

Despite reservations, smoking ban has not increased children's exposure to secondhand smoke

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News